Anabasis Overview
- Year Founded
-
1999
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
2
Anabasis General Information
Description
Developer of therapies for eye. The company focuses on research and development of drugs and therapies for ophthalmology and eyes. It also provides laboratories service for drug development and drug trail.
Contact Information
Website
www.anabasispharma.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Drug Discovery
Drug Delivery
Acquirer
Dompé
Primary Office
- San Martino 12
- 20122 Milan
- Italy
+39 02 0000 0000
Anabasis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Anabasis Patents
Anabasis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-1948217-A2 | Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease | Active | 19-Aug-2005 | 0000000000 | |
| ES-2376992-T3 | Use of nerve growth factor in ophthalmic drops for therapy of pathologies of the central nervous system, such as alzheimer's disease and parkinson's disease | Active | 19-Aug-2005 | 0000000000 | |
| US-20090118177-A1 | Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease | Inactive | 19-Aug-2005 | 0000000000 | 00 |
| EP-1948217-B1 | Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease | Active | 19-Aug-2005 | 0000000000 | |
| ES-2264416-T3 | Use of the nervous growth factor for the preparation of a medicinal product for the therapy of intraocular fabric pathologies. | Inactive | 29-Jan-1999 | A61K38/185 |